The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

Abstract Background P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist fil...

Full description

Bibliographic Details
Main Authors: Christian Friedrich, Klaus Francke, Surinder S. Birring, Jan Willem K. van den Berg, Paul A. Marsden, Lorcan McGarvey, Alice M. Turner, Pascal Wielders, Isabella Gashaw, Stefan Klein, Alyn H. Morice
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Respiratory Research
Subjects:
Cough reflex sensitivity
Airway hyperreactivity
Airway hyperresponsiveness
Receptor pharmacology
P2X3 receptor antagonist
Refractory chronic cough
Online Access:https://doi.org/10.1186/s12931-023-02384-8

Internet

https://doi.org/10.1186/s12931-023-02384-8

Similar Items